<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title-group><journal-title>Therapeutics and Clinical Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20463780</article-id><article-id pub-id-type="pmc">2861440</article-id><article-id pub-id-type="publisher-id">tcrm-6-191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Critical appraisal and clinical utility of atosiban in the management of preterm labor</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sanu</surname><given-names>Olaleye</given-names></name><xref ref-type="aff" rid="af1-tcrm-6-191">1</xref></contrib><contrib contrib-type="author"><name><surname>Lamont</surname><given-names>Ronald F</given-names></name><xref ref-type="corresp" rid="c1-tcrm-6-191"></xref><xref ref-type="aff" rid="af1-tcrm-6-191">1</xref><xref ref-type="aff" rid="af2-tcrm-6-191">2</xref><xref ref-type="aff" rid="af3-tcrm-6-191">3</xref><xref ref-type="aff" rid="af4-tcrm-6-191">4</xref><xref ref-type="aff" rid="af5-tcrm-6-191">5</xref></contrib></contrib-group><aff id="af1-tcrm-6-191"><label>1</label> Department of Obstetrics and Gynaecology, St Mary’s Imperial NHS Trust, London, UK</aff><aff id="af2-tcrm-6-191"><label>2</label> Northwick Park Institute of Medical Research, London, UK</aff><aff id="af3-tcrm-6-191"><label>3</label> Imperial College, London, UK</aff><aff id="af4-tcrm-6-191"><label>4</label> University College, London, UK</aff><aff id="af5-tcrm-6-191"><label>5</label> Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA</aff><author-notes><corresp id="c1-tcrm-6-191">Correspondence: Professor Ronald F Lamont, Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA, Email 
<email>rlamont@med.wayne.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="ppub"><year>2010</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2010</year></pub-date><volume>6</volume><fpage>191</fpage><lpage>199</lpage><permissions><copyright-statement>© 2010 Sanu and Lamont publisher and licensee Dove Medical Press Ltd.</copyright-statement><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="2964" xml_f="4064" txt_i="11" txt_f="1111">Preterm birth is the major cause of perinatal morbidity and mortality in the developed world, and spontaneous preterm labor is the commonest cause of preterm birth. Interventions to treat women in spontaneous preterm labor have not reduced the incidence of preterm births but this may be due to increased risk factors, inclusion of births at the limits of viability, and an increase in the use of elective preterm birth. The role of antibiotics remains unproven. In the largest of the randomized controlled trials, evaluating the use of antibiotics for the prevention of preterm births in women in spontaneous preterm labor, antibiotics against anaerobes and bacterial vaginosis-related organisms were not included, and no objective evidence of abnormal genital tract flora was obtained. Atosiban and nifedipine are the main tocolytic agents used to treat women in spontaneous preterm labor, but atosiban is the tocolytic agent with the fewest maternal – fetal side effects. A well conducted randomized controlled trial comparing atosiban with nifedipine for their effectiveness and safety is needed.</offsets></p></abstract><kwd-group><kwd>preterm labor</kwd><kwd>preterm births</kwd><kwd>management</kwd><kwd>tocolytics</kwd><kwd>atosiban</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="4270" xml_f="4282" txt_i="1119" txt_f="1131">Introduction</offsets></title><p><offsets xml_i="4293" xml_f="4625" txt_i="1132" txt_f="1464">Spontaneous preterm labor (SPTL) – the onset of regular, painful, synchronous uterine contractions before 37 completed weeks of gestation – is a syndrome caused by a multifactorial etiology such as infection/inflammation, uteroplacental ischemia or hemorrhage, uterine overdistention, stress, and immunologically related conditions.</offsets><xref ref-type="bibr" rid="b1-tcrm-6-191"><offsets xml_i="4667" xml_f="4668" txt_i="1464" txt_f="1465">1</offsets></xref><offsets xml_i="4675" xml_f="4735" txt_i="1465" txt_f="1525"> SPTL is the most common cause of antenatal hospitalization,</offsets><xref ref-type="bibr" rid="b2-tcrm-6-191"><offsets xml_i="4777" xml_f="4778" txt_i="1525" txt_f="1526">2</offsets></xref><offsets xml_i="4785" xml_f="4857" txt_i="1526" txt_f="1598"> and of all preterm births (PTBs), about 40% to 50% are related to SPTL.</offsets><xref ref-type="bibr" rid="b3-tcrm-6-191"><offsets xml_i="4899" xml_f="4900" txt_i="1598" txt_f="1599">3</offsets></xref><offsets xml_i="4907" xml_f="4908" txt_i="1599" txt_f="1600">,</offsets><xref ref-type="bibr" rid="b4-tcrm-6-191"><offsets xml_i="4950" xml_f="4951" txt_i="1600" txt_f="1601">4</offsets></xref><offsets xml_i="4958" xml_f="5109" txt_i="1601" txt_f="1752"> In contrast to preterm premature rupture of the membranes and iatrogenic PTB, about 32% of all SPTL is associated with intra-amniotic infection (IAI).</offsets><xref ref-type="bibr" rid="b5-tcrm-6-191"><offsets xml_i="5151" xml_f="5152" txt_i="1752" txt_f="1753">5</offsets></xref><offsets xml_i="5159" xml_f="5231" txt_i="1753" txt_f="1825"> This article reviews the management of SPTL and the role of tocolytics.</offsets></p></sec><sec><title><offsets xml_i="5253" xml_f="5270" txt_i="1827" txt_f="1844">Diagnosis of SPTL</offsets></title><p><offsets xml_i="5281" xml_f="5503" txt_i="1845" txt_f="2067">The accurate diagnosis of SPTL is difficult. Fetal fibronectin (FFN), a glycoprotein found in the chorioamniotic membranes, decidua and cytotrophoblast is elevated in cervicovaginal secretions of women who deliver preterm.</offsets><xref ref-type="bibr" rid="b6-tcrm-6-191"><offsets xml_i="5545" xml_f="5546" txt_i="2067" txt_f="2068">6</offsets></xref><offsets xml_i="5553" xml_f="5909" txt_i="2068" txt_f="2424"> A multicenter trial of 763 women considered to be in SPTL, with a mean gestational age at sampling of 30.3 ± 3.0 weeks, evaluated the negative and positive predictive values of FFN for PTB. The mean gestational age at delivery was 38.4 ± 2.6 weeks, and at least 80% of these women remained undelivered up to 7 days later, irrespective of their FFN status.</offsets><xref ref-type="bibr" rid="b6-tcrm-6-191"><offsets xml_i="5951" xml_f="5952" txt_i="2424" txt_f="2425">6</offsets></xref><offsets xml_i="5959" xml_f="6213" txt_i="2425" txt_f="2679"> The negative predictive value of the FFN test far exceeds the positive predictive value. A meta-analysis of 27 studies using cervicovaginal FFN as a marker for preterm delivery showed a low sensitivity for PTB occurring at less than 34 weeks’ gestation.</offsets><xref ref-type="bibr" rid="b7-tcrm-6-191"><offsets xml_i="6255" xml_f="6256" txt_i="2679" txt_f="2680">7</offsets></xref><offsets xml_i="6263" xml_f="6484" txt_i="2680" txt_f="2901"> A Cochrane systematic review on the use of FFN testing for reducing the risk of PTB showed that management of women in SPTL, based on knowledge of FFN results versus no knowledge, significantly decreased the risk of PTB.</offsets><xref ref-type="bibr" rid="b8-tcrm-6-191"><offsets xml_i="6526" xml_f="6527" txt_i="2901" txt_f="2902">8</offsets></xref><offsets xml_i="6534" xml_f="7021" txt_i="2902" txt_f="3386"> It remains uncertain which interventions are most useful when a positive FFN test is obtained, but length of hospital stay might be reduced and unnecessary tocolytic therapy and in utero transfer prevented if a negative FFN is obtained. The combination of positive FFN test, and the transvaginal ultrasound scan (TVUSS) of women with a short cervical length (&lt;30 mm) may identify those women who may benefit from interventions such as antibiotics and tocolytics which may reduce PTB.</offsets><xref ref-type="bibr" rid="b9-tcrm-6-191"><offsets xml_i="7063" xml_f="7064" txt_i="3386" txt_f="3387">9</offsets></xref><offsets xml_i="7071" xml_f="7072" txt_i="3387" txt_f="3388">–</offsets><xref ref-type="bibr" rid="b11-tcrm-6-191"><offsets xml_i="7115" xml_f="7117" txt_i="3388" txt_f="3390">11</offsets></xref></p></sec><sec><title><offsets xml_i="7146" xml_f="7163" txt_i="3392" txt_f="3409">Infection and PTL</offsets></title><p><offsets xml_i="7174" xml_f="7267" txt_i="3410" txt_f="3503">Chorioamnionitis is often subclinical, and requires amniocentesis to establish the diagnosis.</offsets><xref ref-type="bibr" rid="b12-tcrm-6-191"><offsets xml_i="7310" xml_f="7312" txt_i="3503" txt_f="3505">12</offsets></xref><offsets xml_i="7319" xml_f="7320" txt_i="3505" txt_f="3506">,</offsets><xref ref-type="bibr" rid="b13-tcrm-6-191"><offsets xml_i="7363" xml_f="7365" txt_i="3506" txt_f="3508">13</offsets></xref><offsets xml_i="7372" xml_f="7682" txt_i="3508" txt_f="3818"> Intraamniotic inflammation, defined as negative amniotic fluid (AF) culture with elevated levels of AF interleukin (IL)-1-α, IL 1-β, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α) and IAI (positive AF culture) are both associated with an increased risk of adverse outcomes when compared with idiopathic SPTL.</offsets><xref ref-type="bibr" rid="b14-tcrm-6-191"><offsets xml_i="7725" xml_f="7727" txt_i="3818" txt_f="3820">14</offsets></xref><offsets xml_i="7734" xml_f="7735" txt_i="3820" txt_f="3821">–</offsets><xref ref-type="bibr" rid="b21-tcrm-6-191"><offsets xml_i="7778" xml_f="7780" txt_i="3821" txt_f="3823">21</offsets></xref><offsets xml_i="7787" xml_f="8027" txt_i="3823" txt_f="4063"> These include clinical chorioamnionitis, funisitis, neonatal respiratory distress syndrome (RDS), neonatal pneumonia, intraventricular hemorrhage (≥grade II), bronchopulmonary dysplasia and periventricular leucomalacia, and cerebral palsy.</offsets><xref ref-type="bibr" rid="b5-tcrm-6-191"><offsets xml_i="8069" xml_f="8070" txt_i="4063" txt_f="4064">5</offsets></xref><offsets xml_i="8077" xml_f="8078" txt_i="4064" txt_f="4065">,</offsets><xref ref-type="bibr" rid="b22-tcrm-6-191"><offsets xml_i="8121" xml_f="8123" txt_i="4065" txt_f="4067">22</offsets></xref><offsets xml_i="8130" xml_f="8131" txt_i="4067" txt_f="4068">–</offsets><xref ref-type="bibr" rid="b27-tcrm-6-191"><offsets xml_i="8174" xml_f="8176" txt_i="4068" txt_f="4070">27</offsets></xref></p></sec><sec><title><offsets xml_i="8205" xml_f="8229" txt_i="4072" txt_f="4096">Antibiotics used in SPTL</offsets></title><p><offsets xml_i="8240" xml_f="8546" txt_i="4097" txt_f="4403">Randomized placebo-controlled trials of the use of antibiotics for the treatment of SPTL have yielded conflicting results. The inclusion of antibiotics (clindamycin or metronidazole) which have activity against anaerobes and bacterial vaginosis (BV)-related organisms resulted in prolongation of pregnancy.</offsets><xref ref-type="bibr" rid="b28-tcrm-6-191"><offsets xml_i="8589" xml_f="8591" txt_i="4403" txt_f="4405">28</offsets></xref><offsets xml_i="8598" xml_f="8599" txt_i="4405" txt_f="4406">–</offsets><xref ref-type="bibr" rid="b30-tcrm-6-191"><offsets xml_i="8642" xml_f="8644" txt_i="4406" txt_f="4408">30</offsets></xref><offsets xml_i="8651" xml_f="8704" txt_i="4408" txt_f="4461"> Using a combination of ampicillin and metronidazole,</offsets><xref ref-type="bibr" rid="b28-tcrm-6-191"><offsets xml_i="8747" xml_f="8749" txt_i="4461" txt_f="4463">28</offsets></xref><offsets xml_i="8756" xml_f="8886" txt_i="4463" txt_f="4593"> Svare et al demonstrated that there was a significant prolongation of pregnancy (admission to delivery 47.5 days versus 27 days, </offsets><italic><offsets xml_i="8894" xml_f="8895" txt_i="4593" txt_f="4594">P</offsets></italic><offsets xml_i="8904" xml_f="8973" txt_i="4594" txt_f="4660"> &lt; 0.05) and decreased incidence of preterm birth (42% versus 65% </offsets><italic><offsets xml_i="8981" xml_f="8982" txt_i="4660" txt_f="4661">P</offsets></italic><offsets xml_i="8991" xml_f="9215" txt_i="4661" txt_f="4882"> &lt; 0.05). There was no significant effect on maternal and neonatal infection. Norman et al used ampicillin and metronidazole and showed that pregnancy was prolonged by at least 7 days compared to placebo (63% versus 37%, </offsets><italic><offsets xml_i="9223" xml_f="9224" txt_i="4882" txt_f="4883">P</offsets></italic><offsets xml_i="9233" xml_f="9284" txt_i="4883" txt_f="4934"> = 0.03) and neonatal morbidity was also decreased.</offsets><xref ref-type="bibr" rid="b29-tcrm-6-191"><offsets xml_i="9327" xml_f="9329" txt_i="4934" txt_f="4936">29</offsets></xref><offsets xml_i="9336" xml_f="9502" txt_i="4936" txt_f="5102"> McGregor et al used clindamycin, and detected a statistically significant prolongation of pregnancy in the treated group compared to placebo (35 days versus 25 days </offsets><italic><offsets xml_i="9510" xml_f="9511" txt_i="5102" txt_f="5103">P</offsets></italic><offsets xml_i="9520" xml_f="9529" txt_i="5103" txt_f="5112"> = 0.02).</offsets><xref ref-type="bibr" rid="b30-tcrm-6-191"><offsets xml_i="9572" xml_f="9574" txt_i="5112" txt_f="5114">30</offsets></xref></p><p><offsets xml_i="9588" xml_f="10096" txt_i="5115" txt_f="5623">Oracle II randomized 6295 women into 4 groups – erythromycin only, co-amoxiclav only, combination of erythromycin and co-amoxiclav, and placebo. The primary outcome measure was a composite of neonatal death, chronic lung disease or major cerebral abnormality on ultrasound before discharge from hospital. None of the antibiotics used showed any reduction in the composite outcome compared to placebo. There was no statistically significant difference in the prolongation of pregnancy between the four groups,</offsets><xref ref-type="bibr" rid="b31-tcrm-6-191"><offsets xml_i="10139" xml_f="10141" txt_i="5623" txt_f="5625">31</offsets></xref><offsets xml_i="10148" xml_f="10218" txt_i="5625" txt_f="5695"> but the antibiotics used are not active against BV-related organisms,</offsets><xref ref-type="bibr" rid="b32-tcrm-6-191"><offsets xml_i="10261" xml_f="10263" txt_i="5695" txt_f="5697">32</offsets></xref><offsets xml_i="10270" xml_f="10271" txt_i="5697" txt_f="5698">–</offsets><xref ref-type="bibr" rid="b34-tcrm-6-191"><offsets xml_i="10314" xml_f="10316" txt_i="5698" txt_f="5700">34</offsets></xref><offsets xml_i="10323" xml_f="10372" txt_i="5700" txt_f="5749"> and are not recommended for the treatment of BV.</offsets><xref ref-type="bibr" rid="b35-tcrm-6-191"><offsets xml_i="10415" xml_f="10417" txt_i="5749" txt_f="5751">35</offsets></xref><offsets xml_i="10424" xml_f="10963" txt_i="5751" txt_f="6290"> In addition, no objective measure of abnormal colonization was used, and women with signs of infection were excluded. It is likely therefore, that a minority of women given antibiotics had any infection which needed correction. The median gestational age at delivery within the four groups was beyond 38 completed weeks which raises the question whether the women recruited were really in SPTL. In addition, other trials which did not use antibiotics which are active against BV related organisms and anaerobes have not shown any benefit.</offsets><xref ref-type="bibr" rid="b36-tcrm-6-191"><offsets xml_i="11006" xml_f="11008" txt_i="6290" txt_f="6292">36</offsets></xref><offsets xml_i="11015" xml_f="11016" txt_i="6292" txt_f="6293">–</offsets><xref ref-type="bibr" rid="b41-tcrm-6-191"><offsets xml_i="11059" xml_f="11061" txt_i="6293" txt_f="6295">41</offsets></xref><offsets xml_i="11068" xml_f="11208" txt_i="6295" txt_f="6435"> A Cochrane systematic review of eleven trials on the use of antibiotics for inhibiting PTL concluded that antibiotic use showed no benefit,</offsets><xref ref-type="bibr" rid="b42-tcrm-6-191"><offsets xml_i="11251" xml_f="11253" txt_i="6435" txt_f="6437">42</offsets></xref><offsets xml_i="11260" xml_f="11458" txt_i="6437" txt_f="6635"> partly because of small numbers of women included in the trials which used clindamycin or metronidazole compared to trials which did not use them, and mainly the overwhelming weighting of Oracle Π.</offsets></p></sec><sec><title><offsets xml_i="11480" xml_f="11513" txt_i="6637" txt_f="6670">Antenatal glucocorticoids and PTL</offsets></title><p><offsets xml_i="11524" xml_f="11860" txt_i="6671" txt_f="7007">Administration of a single course of antepartum glucocorticoids to women in SPTL at risk of PTB between 23 and 33 weeks gestation has been proven to reduce the incidences of neonatal RDS, intraventricular hemorrhage, neonatal sepsis, and need for admission to neonatal intensive care unit, necrotizing enterocolitis, and neonatal death.</offsets><xref ref-type="bibr" rid="b43-tcrm-6-191"><offsets xml_i="11903" xml_f="11905" txt_i="7007" txt_f="7009">43</offsets></xref><offsets xml_i="11912" xml_f="12030" txt_i="7009" txt_f="7127"> However, antenatal exposure to glucocorticoids might result in insulin resistance when the offspring reach adulthood.</offsets><xref ref-type="bibr" rid="b44-tcrm-6-191"><offsets xml_i="12073" xml_f="12075" txt_i="7127" txt_f="7129">44</offsets></xref><offsets xml_i="12082" xml_f="12394" txt_i="7129" txt_f="7441"> The benefit observed on the reduced incidence of neonatal RDS does not last beyond 7 days, which supports the importance of accurate diagnosis of SPTL. Repeat courses of antepartum glucocorticoids should be avoided since they can be associated with increased risk of small for gestational age, cesarean section,</offsets><xref ref-type="bibr" rid="b45-tcrm-6-191"><offsets xml_i="12437" xml_f="12439" txt_i="7441" txt_f="7443">45</offsets></xref><offsets xml_i="12446" xml_f="12534" txt_i="7443" txt_f="7531"> and suppression of the maternal and neonatal hypothalamic–pituitary–adrenal (HPA) axis.</offsets><xref ref-type="bibr" rid="b46-tcrm-6-191"><offsets xml_i="12577" xml_f="12579" txt_i="7531" txt_f="7533">46</offsets></xref><offsets xml_i="12586" xml_f="12587" txt_i="7533" txt_f="7534">,</offsets><xref ref-type="bibr" rid="b47-tcrm-6-191"><offsets xml_i="12630" xml_f="12632" txt_i="7534" txt_f="7536">47</offsets></xref><offsets xml_i="12639" xml_f="12817" txt_i="7536" txt_f="7714"> But the Cochrane review on repeat courses of antepartum glucocorticoids showed a reduction in occurrence and severity of any neonatal lung disease, and serious infant morbidity.</offsets><xref ref-type="bibr" rid="b45-tcrm-6-191"><offsets xml_i="12860" xml_f="12862" txt_i="7714" txt_f="7716">45</offsets></xref><offsets xml_i="12869" xml_f="13244" txt_i="7716" txt_f="8091"> In a retrospective analysis of 713 infants (369 and 134 singleton preterm infants delivered at ≤34 and ≥35 weeks gestation respectively, and 210 multiple gestation) whose mothers were exposed to single or multiple courses of antenatal corticosteroids (2–12 courses), a significant reduction in the head circumference (4.6 ± 1.9 mm) was observed in the multiple course group.</offsets><xref ref-type="bibr" rid="b48-tcrm-6-191"><offsets xml_i="13287" xml_f="13289" txt_i="8091" txt_f="8093">48</offsets></xref><offsets xml_i="13296" xml_f="13669" txt_i="8093" txt_f="8466"> A cohort of 541 very preterm infants from singleton pregnancies between 3 and 6 years of age were evaluated, using physical, cognitive, and psychological assessments. Three or more courses of antenatal corticosteroids were associated with increased rates of aggressive/destructive, distractible, and hyperkinetic behavior. The rate of cerebral palsy was, however, reduced.</offsets><xref ref-type="bibr" rid="b49-tcrm-6-191"><offsets xml_i="13712" xml_f="13714" txt_i="8466" txt_f="8468">49</offsets></xref><offsets xml_i="13721" xml_f="13856" txt_i="8468" txt_f="8603"> Nevertheless, repeat courses of antepartum glucocorticoids should be avoided, and the single course should be selective and optimized.</offsets></p></sec><sec><title><offsets xml_i="13878" xml_f="13921" txt_i="8605" txt_f="8648">Pathophysiology/biochemical triggers of PTL</offsets></title><p><offsets xml_i="13932" xml_f="14239" txt_i="8649" txt_f="8956">The precise mechanism of labor in women remains incomplete clinically, endocrinologically and biochemically. Relatively increased plasma levels of corticotrophin releasing hormone – a peptide produced by the placenta – is associated with increased risk of PTBs, but this observation is not specific to SPTL.</offsets><xref ref-type="bibr" rid="b50-tcrm-6-191"><offsets xml_i="14282" xml_f="14284" txt_i="8956" txt_f="8958">50</offsets></xref><offsets xml_i="14291" xml_f="14292" txt_i="8958" txt_f="8959">–</offsets><xref ref-type="bibr" rid="b54-tcrm-6-191"><offsets xml_i="14335" xml_f="14337" txt_i="8959" txt_f="8961">54</offsets></xref><offsets xml_i="14344" xml_f="14507" txt_i="8961" txt_f="9124"> Detection of an early surge or increased levels of salivary estriol is also associated with SPTL, but this surge can occur about 3 weeks before the onset of SPTL.</offsets><xref ref-type="bibr" rid="b51-tcrm-6-191"><offsets xml_i="14550" xml_f="14552" txt_i="9124" txt_f="9126">51</offsets></xref></p><p><offsets xml_i="14566" xml_f="14851" txt_i="9127" txt_f="9412">Experiments on parturition in sheep show that activation of the fetal pituitary adrenal axis results in increased fetal cortisol secretion. Cortisol leads to activation of p450 dependent placental 17 alpha hydroxylase and 17–20 lyase enzymes to cause conversion of C21 to C18 steroids.</offsets><xref ref-type="bibr" rid="b56-tcrm-6-191"><offsets xml_i="14894" xml_f="14896" txt_i="9412" txt_f="9414">56</offsets></xref><offsets xml_i="14903" xml_f="15568" txt_i="9414" txt_f="10079"> Maternal estradiol levels rise, and progesterone levels fall, and this change in estrogen: progesterone ratio leads to increased production of prostaglandins (PGs). Consequently, there is cervical ripening and increased activation of oxytocin receptors, leading to myometrial contractility. However, neither the induction of the placental p450 enzymes nor the fall in progesterone levels has been demonstrated in humans. It is possible that the lack of expression in humans of the placental p450 C17 enzymes serves to maintain the placental production of progesterone, which is reponsible for uterine quiescence and regulation of uterine activity during pregnancy.</offsets></p><p><offsets xml_i="15575" xml_f="15816" txt_i="10080" txt_f="10321">Ovine and primate parturition studies show that increased levels of intrauterine cortisol, of maternal, fetal or the fetoplacental origin induce the expression of PG synthase type 2 (PGHS-2) in the amniochorion, and the supression of the NAD</offsets><sup><offsets xml_i="15821" xml_f="15822" txt_i="10321" txt_f="10322">+</offsets></sup><offsets xml_i="15828" xml_f="16003" txt_i="10322" txt_f="10497"> – dependent PG dehydrogenase in the amnion predominantly from epithelial cells, and to a lesser extent mesenchymal cells. As a result, there is increased production of PGE-2,</offsets><xref ref-type="bibr" rid="b58-tcrm-6-191"><offsets xml_i="16046" xml_f="16048" txt_i="10497" txt_f="10499">58</offsets></xref><offsets xml_i="16055" xml_f="16246" txt_i="10499" txt_f="10690"> and the increased activity of the fetal HPA axis leads to increased production of estriol which activates the PGHS-2 in maternal endometrial epithelium leading to increased levels of PGF2-α.</offsets><xref ref-type="bibr" rid="b57-tcrm-6-191"><offsets xml_i="16289" xml_f="16291" txt_i="10690" txt_f="10692">57</offsets></xref><offsets xml_i="16298" xml_f="16299" txt_i="10692" txt_f="10693">,</offsets><xref ref-type="bibr" rid="b59-tcrm-6-191"><offsets xml_i="16342" xml_f="16344" txt_i="10693" txt_f="10695">59</offsets></xref><offsets xml_i="16351" xml_f="16352" txt_i="10695" txt_f="10696">–</offsets><xref ref-type="bibr" rid="b61-tcrm-6-191"><offsets xml_i="16395" xml_f="16397" txt_i="10696" txt_f="10698">61</offsets></xref></p><p><offsets xml_i="16411" xml_f="16610" txt_i="10699" txt_f="10898">In vitro studies on the regulation of PGHS-2 activity by glucocorticoids in the amnion have yielded conflicting results. Dexamethasone increases the PGHS-2 activity in confluent amnion cell cultures,</offsets><xref ref-type="bibr" rid="b62-tcrm-6-191"><offsets xml_i="16653" xml_f="16655" txt_i="10898" txt_f="10900">62</offsets></xref><offsets xml_i="16662" xml_f="16733" txt_i="10900" txt_f="10971"> and has no effect on PGHS-2 activity in freshly cultured amnion cells.</offsets><xref ref-type="bibr" rid="b63-tcrm-6-191"><offsets xml_i="16776" xml_f="16778" txt_i="10971" txt_f="10973">63</offsets></xref><offsets xml_i="16785" xml_f="17019" txt_i="10973" txt_f="11207"> In addition, dexamethasone suppressed cytokine induced PGHS-Π expression and activity in amnion cells by blocking transcription factor binding at the nuclear factor kappa beta (NF-κβ) and CRE 5′ promoter sequences of the PGHS-2 gene.</offsets><xref ref-type="bibr" rid="b64-tcrm-6-191"><offsets xml_i="17062" xml_f="17064" txt_i="11207" txt_f="11209">64</offsets></xref></p></sec><sec><title><offsets xml_i="17093" xml_f="17117" txt_i="11211" txt_f="11235">The role of progesterone</offsets></title><p><offsets xml_i="17128" xml_f="17466" txt_i="11236" txt_f="11574">The suppression of progesterone receptors (PR) – effectively a functional withdrawal of progesterone – is also linked to the initiation of labor in humans. Two types of PR (A and B) are expressed in the human myometrium at term. It is the expression of PR-A mRNA, relative to PR-B mRNA that leads to functional withdrawal of progesterone.</offsets><xref ref-type="bibr" rid="b65-tcrm-6-191"><offsets xml_i="17509" xml_f="17511" txt_i="11574" txt_f="11576">65</offsets></xref><offsets xml_i="17518" xml_f="17865" txt_i="11576" txt_f="11923"> In vitro studies in mice demonstrate increased transcriptional activities of NF-κβ, in response to inflammatory cytokines such as IL-1β produced by fetal macrophages. Activation of fetal macrophages is believed to be due to secretion into the AF of major lung surfactant protein A and the final effect of these activities is supression of the PR.</offsets><xref ref-type="bibr" rid="b66-tcrm-6-191"><offsets xml_i="17908" xml_f="17910" txt_i="11923" txt_f="11925">66</offsets></xref></p><p><offsets xml_i="17924" xml_f="17975" txt_i="11926" txt_f="11977">In an in vitro study of human tissue, Allport et al</offsets><xref ref-type="bibr" rid="b67-tcrm-6-191"><offsets xml_i="18018" xml_f="18020" txt_i="11977" txt_f="11979">67</offsets></xref><offsets xml_i="18027" xml_f="18440" txt_i="11979" txt_f="12392"> showed that increased NF-κB transcriptional activity leads to activation of the cyclooxygenase (COX) enzyme in the amnion. Two isoforms, one constitutive (COX-1) and the other inducible (COX-2) exist, but in human labor it is the COX-2 enzyme that converts free arachidonic acid (produced from glycophospholipids in the cell membrane by increased phospholipase activity) into the PG precursors – PGH-2 and PGG-2.</offsets><xref ref-type="bibr" rid="b68-tcrm-6-191"><offsets xml_i="18483" xml_f="18485" txt_i="12392" txt_f="12394">68</offsets></xref><offsets xml_i="18492" xml_f="18493" txt_i="12394" txt_f="12395">,</offsets><xref ref-type="bibr" rid="b69-tcrm-6-191"><offsets xml_i="18536" xml_f="18538" txt_i="12395" txt_f="12397">69</offsets></xref><offsets xml_i="18545" xml_f="18762" txt_i="12397" txt_f="12614"> Triggers such as increased cortisol from maternal or fetal stress and/or inflammatory cytokines lead to increased production of PGs which override uterine quiescence, leading to functional withdrawal of progesterone.</offsets></p></sec><sec><title><offsets xml_i="18784" xml_f="18800" txt_i="12616" txt_f="12632">Role of oxytocin</offsets></title><p><offsets xml_i="18811" xml_f="19092" txt_i="12633" txt_f="12914">Coupling of oxytocin (OT), endothelin or prostanoid receptors with the enzyme phosholipase C beta (PLC-β) through the G protein coupled receptors (the most abundant receptors in the uterus) hydrolyzes OT sensitive phosphatidylinositol 4, 5 bisphosphate (PIP2) in the cell membrane.</offsets><xref ref-type="bibr" rid="b58-tcrm-6-191"><offsets xml_i="19135" xml_f="19137" txt_i="12914" txt_f="12916">58</offsets></xref><offsets xml_i="19144" xml_f="19419" txt_i="12916" txt_f="13191"> This process generates two secondary messengers – inositol 1, 4, 5 triphosphate (IP3) and diacyl glycerol. IP3, coupled with specific receptors, releases stored intracellular calcium from the sacroplasmic reticulum. Production of IP3 may further induce influx of calcium (Ca</offsets><sup><offsets xml_i="19424" xml_f="19426" txt_i="13191" txt_f="13193">2+</offsets></sup><offsets xml_i="19432" xml_f="19494" txt_i="13193" txt_f="13255">) from the extracellular space through voltage gated channels.</offsets><xref ref-type="bibr" rid="b70-tcrm-6-191"><offsets xml_i="19537" xml_f="19539" txt_i="13255" txt_f="13257">70</offsets></xref><offsets xml_i="19546" xml_f="19835" txt_i="13257" txt_f="13546"> Activated myosin light chain kinase, under the influence of released intracellular calcium – calmodulin complexes, causes phosphorylation of myosin which then interacts with actin to cause uterine contraction. Dephosphorylation of myosin by myosin phosphatase leads to uterine relaxation.</offsets><xref ref-type="bibr" rid="b58-tcrm-6-191"><offsets xml_i="19878" xml_f="19880" txt_i="13546" txt_f="13548">58</offsets></xref><offsets xml_i="19887" xml_f="19888" txt_i="13548" txt_f="13549">,</offsets><xref ref-type="bibr" rid="b70-tcrm-6-191"><offsets xml_i="19931" xml_f="19933" txt_i="13549" txt_f="13551">70</offsets></xref></p><p><offsets xml_i="19947" xml_f="20118" txt_i="13552" txt_f="13723">The Rho kinases, which belong to the family of G-proteins, also cause uterine contractions by inhibiting myosin phosphatase activity, which leads to calcium sensitization.</offsets><xref ref-type="bibr" rid="b71-tcrm-6-191"><offsets xml_i="20161" xml_f="20163" txt_i="13723" txt_f="13725">71</offsets></xref><offsets xml_i="20170" xml_f="20197" txt_i="13725" txt_f="13752"> In contrast, coupling of β</offsets><sub><offsets xml_i="20202" xml_f="20203" txt_i="13752" txt_f="13753">2</offsets></sub><offsets xml_i="20209" xml_f="20417" txt_i="13753" txt_f="13961">-adrenergic and prostanoid receptors with the enzyme adenylcyclase (AC), possibly through G-protein coupled receptors, lead to production of cyclic nucleotides (cAMP and cGMP) and promotes uterine relaxation.</offsets><xref ref-type="bibr" rid="b58-tcrm-6-191"><offsets xml_i="20460" xml_f="20462" txt_i="13961" txt_f="13963">58</offsets></xref><offsets xml_i="20469" xml_f="20470" txt_i="13963" txt_f="13964">,</offsets><xref ref-type="bibr" rid="b72-tcrm-6-191"><offsets xml_i="20513" xml_f="20515" txt_i="13964" txt_f="13966">72</offsets></xref><offsets xml_i="20522" xml_f="20699" txt_i="13966" txt_f="14143"> Phosphodiesterase (PDE)-4, an isozyme of PDE predominantly expressed in the pregnant uterus, inhibits cAMP production, but progesterone promotes AC and inhibits PDE-4 activity.</offsets><xref ref-type="bibr" rid="b73-tcrm-6-191"><offsets xml_i="20742" xml_f="20744" txt_i="14143" txt_f="14145">73</offsets></xref><offsets xml_i="20751" xml_f="20824" txt_i="14145" txt_f="14218"> Summary of some of these biochemical events leading to PTL are shown in </offsets><xref ref-type="fig" rid="f1-tcrm-6-191"><offsets xml_i="20865" xml_f="20873" txt_i="14218" txt_f="14226">Figure 1</offsets></xref><offsets xml_i="20880" xml_f="20881" txt_i="14226" txt_f="14227">.</offsets></p></sec><sec><title><offsets xml_i="20903" xml_f="20932" txt_i="14229" txt_f="14258">Role of tocolytics – atosiban</offsets></title><p><offsets xml_i="20943" xml_f="21224" txt_i="14259" txt_f="14540">OT is a potent uterotonic hormone that is secreted from the posterior pituitary gland. Although increased levels of OT are not evident during labor, the uterine contractile effect of oxytocin relies on activated OT receptors in the presence of increased estrogen and PG production.</offsets><xref ref-type="bibr" rid="b74-tcrm-6-191"><offsets xml_i="21267" xml_f="21269" txt_i="14540" txt_f="14542">74</offsets></xref><offsets xml_i="21276" xml_f="21393" txt_i="14542" txt_f="14659"> Atosiban is a nonapeptide, desamino-OT analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra).</offsets><xref ref-type="bibr" rid="b75-tcrm-6-191"><offsets xml_i="21436" xml_f="21438" txt_i="14659" txt_f="14661">75</offsets></xref><offsets xml_i="21445" xml_f="21446" txt_i="14661" txt_f="14662">–</offsets><xref ref-type="bibr" rid="b78-tcrm-6-191"><offsets xml_i="21489" xml_f="21491" txt_i="14662" txt_f="14664">78</offsets></xref><offsets xml_i="21498" xml_f="21582" txt_i="14664" txt_f="14748"> Atosiban inhibits the OT-mediated release of IP3 from the myometrial cell membrane.</offsets><xref ref-type="bibr" rid="b75-tcrm-6-191"><offsets xml_i="21625" xml_f="21627" txt_i="14748" txt_f="14750">75</offsets></xref><offsets xml_i="21634" xml_f="21783" txt_i="14750" txt_f="14899"> As a result, there is reduced release of intracellular, stored calcium from the sacroplasmic reticulum of myometrial cells, and reduced influx of Ca</offsets><sup><offsets xml_i="21788" xml_f="21790" txt_i="14899" txt_f="14901">2+</offsets></sup><offsets xml_i="21796" xml_f="21943" txt_i="14901" txt_f="15048"> from the extracellular space through voltage gated channels. In addition, atosiban suppresses OT-mediated release of PGE and PGF from the decidua.</offsets><xref ref-type="bibr" rid="b79-tcrm-6-191"><offsets xml_i="21986" xml_f="21988" txt_i="15048" txt_f="15050">79</offsets></xref><offsets xml_i="21995" xml_f="21996" txt_i="15050" txt_f="15051">,</offsets><xref ref-type="bibr" rid="b80-tcrm-6-191"><offsets xml_i="22039" xml_f="22041" txt_i="15051" txt_f="15053">80</offsets></xref></p></sec><sec><title><offsets xml_i="22070" xml_f="22094" txt_i="15055" txt_f="15079">Phase II and III studies</offsets></title><p><offsets xml_i="22105" xml_f="22368" txt_i="15080" txt_f="15343">Peak plasma concentrations of atosiban was achieved at 2 to 8 minutes following intravenous (IV) administration (10 nmol/kg body weight) compared to peak concentration at 10 to 45 minutes following intranasal administration of atosiban at 100 nmol/kg body weight.</offsets><xref ref-type="bibr" rid="b81-tcrm-6-191"><offsets xml_i="22411" xml_f="22413" txt_i="15343" txt_f="15345">81</offsets></xref><offsets xml_i="22420" xml_f="22721" txt_i="15345" txt_f="15646"> Goodwin et al showed that following IV infusion of atosiban (300 μ/min) in women between 20 and 36 weeks’ gestation, and in whom contractions were absent for 6 hours or maximum infusion length of 12 hours, plasma atosiban concentrations reached steady state within 1 hour of the start of IV infusion.</offsets><xref ref-type="bibr" rid="b82-tcrm-6-191"><offsets xml_i="22764" xml_f="22766" txt_i="15646" txt_f="15648">82</offsets></xref><offsets xml_i="22773" xml_f="23474" txt_i="15648" txt_f="16349"> The decrease in uterine activity in the first 4 hours of IV infusion was directly proportional to the duration of infusion. At the completion of infusion, plasma atosiban levels declined in a bi-exponential manner with initial and terminal half lives of 13 ± 3 and 102 ± 18 minutes, respectively. In a phase II randomized placebo controlled trial of the effect of atosiban on premature uterine activity (20 to 36 weeks gestation), a 2-hour infusion of atosiban led to a statistically significant decline in the frequency of uterine contractions, suggesting that OT plays a role in the maintenance of PTL. The only adverse outcome reported in the atosiban group was nausea and vomiting in one patient.</offsets><xref ref-type="bibr" rid="b83-tcrm-6-191"><offsets xml_i="23517" xml_f="23519" txt_i="16349" txt_f="16351">83</offsets></xref><offsets xml_i="23526" xml_f="24214" txt_i="16351" txt_f="17039"> In a phase III randomized controlled trial of the effect of atosiban on PTL (20 to 34 weeks), which allowed tocolytic rescue if after 1 hour of atosiban or placebo infusion, premature labor continued, the primary end-point was the time to delivery or therapeutic failure (progression of labor requiring an alternative tocolytic). There was no statistically significant difference between the two groups for the primary end-point. The secondary endpoints were the proportions of women who were successfully treated at 24 hours, 48 hours and 7 days after commencing atosiban or placebo infusion. The proportions were significantly higher in the atosiban group: 73% versus 58% at 24 hours (</offsets><italic><offsets xml_i="24222" xml_f="24223" txt_i="17039" txt_f="17040">P</offsets></italic><offsets xml_i="24232" xml_f="24274" txt_i="17040" txt_f="17079"> &lt; 0.001), 67% versus 56% at 48 hours (</offsets><italic><offsets xml_i="24282" xml_f="24283" txt_i="17079" txt_f="17080">P</offsets></italic><offsets xml_i="24292" xml_f="24333" txt_i="17080" txt_f="17121"> = 0.008), and 62% versus 49% at 7 days (</offsets><italic><offsets xml_i="24341" xml_f="24342" txt_i="17121" txt_f="17122">P</offsets></italic><offsets xml_i="24351" xml_f="24571" txt_i="17122" txt_f="17339"> = 0.003). Compared to placebo, the effect of atosiban on prolongation of pregnancy up to 7 days was more evident in pregnancies ≥28 weeks completed weeks of gestation; 65% versus 48%, and 51% versus 59% at &lt;28 weeks.</offsets><xref ref-type="bibr" rid="b84-tcrm-6-191"><offsets xml_i="24614" xml_f="24616" txt_i="17339" txt_f="17341">84</offsets></xref><offsets xml_i="24623" xml_f="24882" txt_i="17341" txt_f="17600"> These findings emphasize the fact that VOTras play a role in the maintenance of SPTL, yet other mechanisms are also involved. The perinatal mortality rate was 2.1% in the atosiban group, compared to 1.4% in the placebo group with or without tocolytic rescue.</offsets><xref ref-type="bibr" rid="b84-tcrm-6-191"><offsets xml_i="24925" xml_f="24927" txt_i="17600" txt_f="17602">84</offsets></xref><offsets xml_i="24934" xml_f="25150" txt_i="17602" txt_f="17818"> However, the randomization was not stratified according to gestational age, which resulted in an excess of extremely premature infants at a more advanced stage of labor in the atosiban group, and the Cochrane Review</offsets><xref ref-type="bibr" rid="b85-tcrm-6-191"><offsets xml_i="25193" xml_f="25195" txt_i="17818" txt_f="17820">85</offsets></xref><offsets xml_i="25202" xml_f="25251" txt_i="17820" txt_f="17869"> has been criticized for their use of these data.</offsets><xref ref-type="bibr" rid="b77-tcrm-6-191"><offsets xml_i="25294" xml_f="25296" txt_i="17869" txt_f="17871">77</offsets></xref><offsets xml_i="25303" xml_f="25737" txt_i="17871" txt_f="18305"> In a randomized controlled trial of women who, after successful treatment with atosiban, had a maintenance subcutaneous infusion of atosiban or placebo, the use of atosiban resulted in a statistically significant prolongation of uterine quiescence, compared to placebo (median of 32.6 days versus 27.6 days). Women in the atosiban group had higher incidence injection site reactions (70% versus 48%) during the maintenance treatment.</offsets><xref ref-type="bibr" rid="b86-tcrm-6-191"><offsets xml_i="25780" xml_f="25782" txt_i="18305" txt_f="18307">86</offsets></xref></p></sec><sec><title><offsets xml_i="25811" xml_f="25871" txt_i="18309" txt_f="18369">Worldwide comparative trial of atosiban versus beta-agonists</offsets></title><p><offsets xml_i="25882" xml_f="26830" txt_i="18370" txt_f="19318">A worldwide, multinational, multicenter, double-dummy, comparative controlled study compared the effectiveness and safety of atosiban with conventional beta-agonist therapy (ritodrine, salbutamol or terbutaline) in the treatment of SPTL. Alternative tocolytic therapy could be used, if there were unacceptable side effects or if labor progressed. The methodology also permitted re-treatment in cases in which tocolysis had been initially successful provided the patient still fulfilled the protocol requirements. The study showed that atosiban was as effective as the beta-agonists in delaying delivery for 48 hours or 7 days. The need for rescue therapy was significantly reduced in the atosiban group compared with the beta-agonist group, at 48 hours and 7 days after initiation of tocolytic therapy. Maternal side effects, especially cardiovascular adverse events, occurred 10 times more frequently in the beta-agonist group (8.3% versus 81.2%, </offsets><italic><offsets xml_i="26838" xml_f="26839" txt_i="19318" txt_f="19319">P</offsets></italic><offsets xml_i="26848" xml_f="27062" txt_i="19319" txt_f="19530"> &lt; 0.001).and there was a 15-fold increased need for discontinuation of therapy due to unacceptable side effects. There was no statistically significant difference in the perinatal morbidity and mortality rates.</offsets><xref ref-type="bibr" rid="b87-tcrm-6-191"><offsets xml_i="27105" xml_f="27107" txt_i="19530" txt_f="19532">87</offsets></xref></p></sec><sec><title><offsets xml_i="27136" xml_f="27162" txt_i="19534" txt_f="19560">Atosiban versus nifedipine</offsets></title><p><offsets xml_i="27173" xml_f="27784" txt_i="19561" txt_f="20172">A meta-analysis using a “virtual” indirect comparison of atosiban versus the calcium channel blocker (CCB) nifedipine, included 9 randomized trials evaluating the effectiveness of nifedipine versus beta-agonists (different dosage, route and release formulation of nifedipine were used), and four trials of atosiban versus beta-agonists and concluded that the use of nifedipine was associated with a significant reduction in respiratory distress syndrome compared to atosiban. However, the number of women who remained undelivered by 48 hours was not statistically significantly different between the two groups.</offsets><xref ref-type="bibr" rid="b88-tcrm-6-191"><offsets xml_i="27827" xml_f="27829" txt_i="20172" txt_f="20174">88</offsets></xref><offsets xml_i="27836" xml_f="29252" txt_i="20174" txt_f="21590"> The true effect of randomization can be lost when comparing the effectiveness of two tocolytics in this indirect way, and the authors acknowledged the shortcomings of such an analysis and that a number of assumptions were made in the comparisons. A small interventional randomized controlled trial, of 63 women, comparing atosiban with nifedipine for the treatment of SPTL (24 weeks to 35 weeks gestation) permitted tocolytic rescue after 1 hour for failed tocolysis by the assigned drug. Tocolytic agents were administered until uterine quiescence was achieved, and maintenance tocolytic regimes were not specified. The main outcome measure was the proportion of women who did not deliver, or who required alternative tocolytic therapy to avoid side effects 48 hours and 7 days after initiation of treatment. The study showed that there was no statistically significant difference between the two groups in delay of delivery for 48 hours up to 7 days. There was no statistically significant difference between the groups in the need for rescue tocolytic therapy. Nifedipine achieved uterine quiescence faster than atosiban (mean of 2.2 hours ± 0.93 versus 4.2 hours ± 1.1). Nausea occurred more frequently in the atosiban group. Headache, flushing, palpitation and hypotension were significantly increased in the nifedipine goup. Perinatal and neonatal outcomes were not significantly different between the groups.</offsets><xref ref-type="bibr" rid="b89-tcrm-6-191"><offsets xml_i="29295" xml_f="29297" txt_i="21590" txt_f="21592">89</offsets></xref><offsets xml_i="29304" xml_f="29847" txt_i="21592" txt_f="22135"> Another randomized controlled trial of 80 women, compared the efficacy of atosiban and nifedipine for the delay of delivery in women with PTL between 26 weeks and 34 completed weeks of gestation. Atosiban was as effective as nifedipine for delay of delivery for 48 hours and 7 days, and with minimal maternal side effects. Rescue tocolytic and maintenance therapy were not part of the protocol. Hypotension (27.5%), palpitations (7.5%) and maternal tachycardia (7.5%) were reported in the nifedipine group and none (0%) in the atosiban group.</offsets><xref ref-type="bibr" rid="b90-tcrm-6-191"><offsets xml_i="29890" xml_f="29892" txt_i="22135" txt_f="22137">90</offsets></xref></p></sec><sec><title><offsets xml_i="29921" xml_f="29950" txt_i="22139" txt_f="22168">Adverse effects of tocolytics</offsets></title><p><offsets xml_i="29961" xml_f="30193" txt_i="22169" txt_f="22401">The posterior pituitary hormones, OT and arginine vasopressin, differ in structure by only two amino acids, and atosiban influences physiological effects of arginine vasopressin on the feto–maternal cardiovascular and renal systems.</offsets><xref ref-type="bibr" rid="b91-tcrm-6-191"><offsets xml_i="30236" xml_f="30238" txt_i="22401" txt_f="22403">91</offsets></xref><offsets xml_i="30245" xml_f="30366" txt_i="22403" txt_f="22524"> In late-gestation sheep, the administration of atosiban for 1 hour failed to induce fetomaternal cardiovascular changes.</offsets><xref ref-type="bibr" rid="b92-tcrm-6-191"><offsets xml_i="30409" xml_f="30411" txt_i="22524" txt_f="22526">92</offsets></xref><offsets xml_i="30418" xml_f="30592" txt_i="22526" txt_f="22700"> IV atosiban (300 μg/min) used in women scheduled for elective cesarean section demonstrated no significant effect on the umbilical cord blood gases, and maternal hematocrit.</offsets><xref ref-type="bibr" rid="b93-tcrm-6-191"><offsets xml_i="30635" xml_f="30637" txt_i="22700" txt_f="22702">93</offsets></xref><offsets xml_i="30644" xml_f="30758" txt_i="22702" txt_f="22816"> In contrast Blea et al found that in pregnant ewes, IV nifedipine was associated with fetal hypoxia and acidosis.</offsets><xref ref-type="bibr" rid="b94-tcrm-6-191"><offsets xml_i="30801" xml_f="30803" txt_i="22816" txt_f="22818">94</offsets></xref><offsets xml_i="30810" xml_f="30971" txt_i="22818" txt_f="22979"> There are also concerns with respect to the number of published reports of adverse feto–maternal events after the use of CCBs, compared to the use of atosiban. </offsets><xref ref-type="bibr" rid="b95-tcrm-6-191"><offsets xml_i="31014" xml_f="31016" txt_i="22979" txt_f="22981">95</offsets></xref><offsets xml_i="31023" xml_f="31024" txt_i="22981" txt_f="22982">–</offsets><xref ref-type="bibr" rid="b107-tcrm-6-191"><offsets xml_i="31068" xml_f="31071" txt_i="22982" txt_f="22985">107</offsets></xref><offsets xml_i="31078" xml_f="31502" txt_i="22985" txt_f="23409"> In children aged 9 to 12 years who were exposed to nifedipine in utero compared to others with in utero exposure to ritodrine, measures of behavioural–emotional problems, motor function, parenting problems and education failed to demonstrate any significant difference between the two groups. The same comparison is needed to evaluate the long-term outcomes in children exposed to atosiban in utero, compared to nifedipine.</offsets><xref ref-type="bibr" rid="b108-tcrm-6-191"><offsets xml_i="31546" xml_f="31549" txt_i="23409" txt_f="23412">108</offsets></xref></p><p><offsets xml_i="31563" xml_f="31667" txt_i="23413" txt_f="23517">For the treatment of SPTL, a complete course of atosiban is much more expensive than that of nifedipine.</offsets><xref ref-type="bibr" rid="b109-tcrm-6-191"><offsets xml_i="31711" xml_f="31714" txt_i="23517" txt_f="23520">109</offsets></xref><offsets xml_i="31721" xml_f="31830" txt_i="23520" txt_f="23629"> There is no doubt that a well conducted randomized controlled trial of atosiban versus nifedipine is needed.</offsets><xref ref-type="bibr" rid="b110-tcrm-6-191"><offsets xml_i="31874" xml_f="31877" txt_i="23629" txt_f="23632">110</offsets></xref></p></sec><sec><title><offsets xml_i="31906" xml_f="31916" txt_i="23634" txt_f="23644">Conclusion</offsets></title><p></p></sec></body><back><fn-group><fn><p><bold>Disclosures</bold></p><p>The authors declare no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-tcrm-6-191"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Espinoza</surname><given-names>J</given-names></name><name><surname>Kusanovic</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>The preterm parturition syndrome</article-title><source>BJOG</source><year>2006</year><volume>113</volume><issue>Suppl 3</issue><fpage>17</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17206962</pub-id></mixed-citation></ref><ref id="b2-tcrm-6-191"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savita</surname><given-names>DA</given-names></name><name><surname>Blackmore</surname><given-names>CA</given-names></name><name><surname>Thorp</surname><given-names>JM</given-names></name></person-group><article-title>Epidemiologic characteristics of preterm Delivery: etiology heterogeneity</article-title><source>Am J Obstet Gynecol</source><year>1991</year><fpage>467</fpage><lpage>471</lpage></mixed-citation></ref><ref id="b3-tcrm-6-191"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>JM</given-names></name><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Davis</surname><given-names>RO</given-names></name><name><surname>Cooper</surname><given-names>RL</given-names></name><name><surname>Winker</surname><given-names>CL</given-names></name><name><surname>Hauth</surname><given-names>JC</given-names></name></person-group><article-title>Etiologies of preterm birth in an indigent population: is prevention a logical expectation</article-title><source>Obstet Gynecol</source><year>1991</year><volume>77</volume><fpage>343</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">1992395</pub-id></mixed-citation></ref><ref id="b4-tcrm-6-191"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JA</given-names></name><name><surname>Hamilton</surname><given-names>BE</given-names></name><name><surname>Sutton</surname><given-names>PD</given-names></name><etal></etal></person-group><article-title>Births: final data for 2005</article-title><source>Natl Vital Stat Rep</source><year>2007</year><volume>56</volume><fpage>1</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">18277471</pub-id></mixed-citation></ref><ref id="b5-tcrm-6-191"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Moon</surname><given-names>JB</given-names></name><etal></etal></person-group><article-title>Clinical significance of intraamniotic inflammation in patients with preterm labor and intact membranes</article-title><source>Am J Obstet Gynecol</source><year>2001</year><volume>185</volume><fpage>1130</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">11717646</pub-id></mixed-citation></ref><ref id="b6-tcrm-6-191"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peaceman</surname><given-names>AM</given-names></name><name><surname>Andrews</surname><given-names>WW</given-names></name><name><surname>Thorp</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial</article-title><source>Am J Obstet Gynecol</source><year>1997</year><volume>177</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">9240576</pub-id></mixed-citation></ref><ref id="b7-tcrm-6-191"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitich</surname><given-names>H</given-names></name><name><surname>Egarter</surname><given-names>C</given-names></name><name><surname>Kaider</surname><given-names>A</given-names></name><name><surname>Hohlagschwandtner</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>P</given-names></name><name><surname>Husslein</surname><given-names>P</given-names></name></person-group><article-title>Cervicovaginal fetal fibronectin as a marker for preterm delivery: A meta-analysis</article-title><source>Am J Obstet Gynecol</source><year>1999</year><volume>180</volume><fpage>1169</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">10329873</pub-id></mixed-citation></ref><ref id="b8-tcrm-6-191"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghella</surname><given-names>V</given-names></name><name><surname>Hayes</surname><given-names>E</given-names></name><name><surname>Visintine</surname><given-names>J</given-names></name><name><surname>Baxter</surname><given-names>J</given-names></name></person-group><article-title>Fetal fibronectin testing for reducing the risk of preterm birth</article-title><source>Cochrane Database Syst Rev</source><year>2008</year><issue>4</issue></mixed-citation></ref><ref id="b9-tcrm-6-191"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Medina</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes</article-title><source>Am J Obstet Gynecol</source><year>2005</year><volume>192</volume><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">15695971</pub-id></mixed-citation></ref><ref id="b10-tcrm-6-191"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Visintine</surname><given-names>J</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Boyle</surname><given-names>K</given-names></name><name><surname>Berghella</surname><given-names>V</given-names></name></person-group><article-title>Use of fetal fibronectin and transvaginal ultrasound cervical length to triage women with suspected preterm labor: A randomised trial</article-title><source>Am J Obstet Gynecol</source><year>2006</year><volume>195</volume><issue>6 Suppl 1</issue><fpage>S67</fpage></mixed-citation></ref><ref id="b11-tcrm-6-191"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ness</surname><given-names>A</given-names></name><name><surname>Visintine</surname><given-names>J</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Does Knowledge of cervical length and fetal fibronectin affect the management of women with threatened preterm labour? A randomised trial</article-title><source>Am J Obstet Gynecol</source><year>2007</year><volume>197</volume><fpage>426.e1</fpage><lpage>426.e7</lpage><pub-id pub-id-type="pmid">17904989</pub-id></mixed-citation></ref><ref id="b12-tcrm-6-191"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allbert</surname><given-names>JR</given-names></name><name><surname>Naef</surname><given-names>RW</given-names></name><name><surname>Perry</surname><given-names>KG</given-names></name><name><surname>Magann</surname><given-names>EF</given-names></name><name><surname>Whitworth</surname><given-names>NS</given-names></name><name><surname>Morrison</surname><given-names>JC</given-names></name></person-group><article-title>Amniotic fluid interleukin-6 and interleukin-8 levels predict the success of tocolysis in patients with preterm labor</article-title><source>J Soc Gynecol Invest</source><year>1994</year><volume>1</volume><fpage>264</fpage><lpage>268</lpage></mixed-citation></ref><ref id="b13-tcrm-6-191"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>RS</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name><name><surname>Eschenbach</surname><given-names>DA</given-names></name><name><surname>Sweet</surname><given-names>RL</given-names></name></person-group><article-title>A review of premature birth and subclinical infection</article-title><source>Am J Obstet Gynecol</source><year>1992</year><volume>166</volume><fpage>1515</fpage><lpage>1528</lpage><pub-id pub-id-type="pmid">1595807</pub-id></mixed-citation></ref><ref id="b14-tcrm-6-191"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Mazor</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>YK</given-names></name><etal></etal></person-group><article-title>Infection in the pathogenesis of preterm labor</article-title><source>Semin Perinatol</source><year>1988</year><volume>12</volume><fpage>262</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">3065940</pub-id></mixed-citation></ref><ref id="b15-tcrm-6-191"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Sirtori</surname><given-names>M</given-names></name><name><surname>Oyarzun</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes</article-title><source>Am J Obstet Gynecol</source><year>1989</year><volume>161</volume><fpage>817</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">2675611</pub-id></mixed-citation></ref><ref id="b16-tcrm-6-191"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonclaves</surname><given-names>LF</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name></person-group><article-title>Intrauterine infection and prematurity</article-title><source>Ment Retard Dev Disabil Res Rev</source><year>2002</year><volume>8</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11921380</pub-id></mixed-citation></ref><ref id="b17-tcrm-6-191"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Ghezzi</surname><given-names>F</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Munoz</surname><given-names>H</given-names></name><name><surname>Tolosa</surname><given-names>JE</given-names></name><name><surname>Rojas</surname><given-names>I</given-names></name></person-group><article-title>Premature labor and intra-amniotic infection. Clinical aspects and role of cytokines in diagnosis and pathophysiology</article-title><source>Clin Perinatol</source><year>1995</year><volume>22</volume><fpage>281</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">7671540</pub-id></mixed-citation></ref><ref id="b18-tcrm-6-191"><label>18</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Durum</surname><given-names>SK</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><etal></etal></person-group><article-title>Interleukin-1: a signal for the initiation of labour in chorioamnionitis</article-title><conf-name>33rd Annual Meeting for the Society for Gynecologic Investigation</conf-name><conf-date>19–22 March 1986</conf-date><conf-loc>Toronto, Ontario Canada</conf-loc></mixed-citation></ref><ref id="b19-tcrm-6-191"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Manogue</surname><given-names>KR</given-names></name><name><surname>Mitchell</surname><given-names>MD</given-names></name><etal></etal></person-group><article-title>Cachectin-tumour necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor</article-title><source>Am J Obstet Gynecol</source><year>1989</year><volume>161</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">2764054</pub-id></mixed-citation></ref><ref id="b20-tcrm-6-191"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravett</surname><given-names>MG</given-names></name><name><surname>Witkin</surname><given-names>SS</given-names></name><name><surname>Haluska</surname><given-names>GJ</given-names></name><name><surname>Edwards</surname><given-names>JL</given-names></name><name><surname>Cook</surname><given-names>MJ</given-names></name><name><surname>Novy</surname><given-names>MJ</given-names></name></person-group><article-title>An experimental model for intraamniotic infection and preterm labor in rhesus monkeys</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>171</volume><fpage>1600</fpage><lpage>1667</lpage></mixed-citation></ref><ref id="b21-tcrm-6-191"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coultrip</surname><given-names>LL</given-names></name><name><surname>Lien</surname><given-names>JM</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Kapernick</surname><given-names>P</given-names></name><name><surname>Khoury</surname><given-names>A</given-names></name><name><surname>Grossman</surname><given-names>JH</given-names></name></person-group><article-title>The value of amniotic fluid interleukin-6 determination in patients with preterm labor and intact membranes in the detection of microbial invasion of the amniotic cavity</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>171</volume><fpage>901</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">7943100</pub-id></mixed-citation></ref><ref id="b22-tcrm-6-191"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>172</volume><fpage>960</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">7892891</pub-id></mixed-citation></ref><ref id="b23-tcrm-6-191"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>High expression of tumour necrosis factor-α and interleukin-6 in periventricular leukomalacia</article-title><source>Am J Obstet Gynecol</source><year>1997</year><volume>177</volume><fpage>406</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">9290459</pub-id></mixed-citation></ref><ref id="b24-tcrm-6-191"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>BH</given-names></name><name><surname>Jun</surname><given-names>JK</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Amniotic fluid inflammatory cytokines (interleukin-6, interleukin 1-β, and tumour necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy</article-title><source>Am J Obstet Gynecol</source><year>1997</year><volume>177</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9240577</pub-id></mixed-citation></ref><ref id="b25-tcrm-6-191"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Figueroa</surname><given-names>R</given-names></name><name><surname>Garry</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Elevated amniotic fluid interleulin-6 as a predictor of neonatal periventricular leukomalacia and intraventricular hemorrhage</article-title><source>J Matern Fetal Invest</source><year>1998</year><volume>8</volume><fpage>101</fpage><lpage>107</lpage></mixed-citation></ref><ref id="b26-tcrm-6-191"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitti</surname><given-names>J</given-names></name><name><surname>Tarczy-Hornoch</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Hillier</surname><given-names>SL</given-names></name><name><surname>Aura</surname><given-names>J</given-names></name><name><surname>Eschenbach</surname><given-names>DA</given-names></name></person-group><article-title>Amniotic fluid infection, cytokines and adverse outcome among infants at 34 weeks’ gestation or less</article-title><source>Obstet Gynecol</source><year>2001</year><volume>98</volume><fpage>1080</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">11755557</pub-id></mixed-citation></ref><ref id="b27-tcrm-6-191"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challis</surname><given-names>JR</given-names></name><name><surname>Lye</surname><given-names>SJ</given-names></name><name><surname>Gibb</surname><given-names>W</given-names></name><name><surname>Whittle</surname><given-names>W</given-names></name><name><surname>Patel</surname><given-names>F</given-names></name><name><surname>Alfaidy</surname><given-names>N</given-names></name></person-group><article-title>Understanding preterm labor</article-title><source>Ann N Y Acad Sci</source><year>2001</year><volume>943</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">11594542</pub-id></mixed-citation></ref><ref id="b28-tcrm-6-191"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svare</surname><given-names>J</given-names></name><name><surname>Langhoff-Roos</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Ampicillin-metronidazole treatment in idiopathic preterm labor: a randomised controlled multicentre trial</article-title><source>BJOG</source><year>1997</year><volume>104</volume><fpage>892</fpage><lpage>897</lpage></mixed-citation></ref><ref id="b29-tcrm-6-191"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>K</given-names></name><name><surname>Pattinson</surname><given-names>RC</given-names></name><name><surname>de Souza</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>P</given-names></name><name><surname>Moller</surname><given-names>G</given-names></name><name><surname>Kirsten</surname><given-names>G</given-names></name></person-group><article-title>Ampicillin and metronidazole treatment in preterm labor: a multicentre, randomised controlled trial</article-title><source>BJOG</source><year>1994</year><volume>101</volume><fpage>404</fpage><lpage>408</lpage></mixed-citation></ref><ref id="b30-tcrm-6-191"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcgregor</surname><given-names>JA</given-names></name><name><surname>French</surname><given-names>JI</given-names></name><name><surname>Seo</surname><given-names>K</given-names></name></person-group><article-title>Adjunctive clindamycin therapy for preterm labor: results of a double-blind, placebo-controlled trial</article-title><source>Am J Obstet Gynecol</source><year>1991</year><volume>165</volume><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">1951545</pub-id></mixed-citation></ref><ref id="b31-tcrm-6-191"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenyon</surname><given-names>SL</given-names></name><name><surname>Taylor</surname><given-names>DJ</given-names></name><name><surname>Tarnow-Mordi</surname><given-names>W</given-names></name></person-group><article-title>Broad-spectrum antibiotics for spontaneous preterm labor: the ORACLE 11 randomised trial</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>991</fpage><lpage>996</lpage></mixed-citation></ref><ref id="b32-tcrm-6-191"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>Can antibiotics prevent preterm birth-pro and con debate</article-title><source>BJOG</source><year>2005</year><volume>112</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15715599</pub-id></mixed-citation></ref><ref id="b33-tcrm-6-191"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>Antibiotics used in women at risk of preterm birth</article-title><source>Am J Obstet Gynecol</source><year>2008</year><volume>199</volume><fpage>583</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">19084094</pub-id></mixed-citation></ref><ref id="b34-tcrm-6-191"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>Association between cerebral palsy and erythromycin</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>26</fpage><pub-id pub-id-type="pmid">19121713</pub-id></mixed-citation></ref><ref id="b35-tcrm-6-191"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Workowski</surname><given-names>KA</given-names></name><name><surname>Berman</surname><given-names>SM</given-names></name></person-group><article-title>Sexually transmitted disease treatment guidelines</article-title><source>MMWR Recomm Rep</source><year>2006</year><volume>55</volume><fpage>1</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16888612</pub-id></mixed-citation></ref><ref id="b36-tcrm-6-191"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>ER</given-names></name><name><surname>Dinsmoor</surname><given-names>MJ</given-names></name><name><surname>Gibbs</surname><given-names>RS</given-names></name></person-group><article-title>A randomised, blinded, placebo-controlled trial of antibiotics in idiopathic preterm labor</article-title><source>Obstet Gynecol</source><year>1989</year><volume>74</volume><fpage>562</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">2677862</pub-id></mixed-citation></ref><ref id="b37-tcrm-6-191"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>ER</given-names></name><name><surname>Shields</surname><given-names>L</given-names></name><name><surname>Ridgway</surname><given-names>LE</given-names></name><name><surname>Berkus</surname><given-names>MD</given-names></name><name><surname>Elliott</surname><given-names>BD</given-names></name></person-group><article-title>Combination antibiotics and indomethacin in idiopathic preterm labor: a randomised double blind clinical trial</article-title><source>Am J Obstet Gynecol</source><year>1991</year><volume>165</volume><fpage>1753</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">1750473</pub-id></mixed-citation></ref><ref id="b38-tcrm-6-191"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Sibai</surname><given-names>B</given-names></name><name><surname>Caritis</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Antibiotic treatment of preterm labour with intact membranes: a multicenter, randomised, double blind, placebo-controlled trial</article-title><source>Am J Obstet Gynecol</source><year>1993</year><volume>169</volume><fpage>764</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">8238130</pub-id></mixed-citation></ref><ref id="b39-tcrm-6-191"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Samuels</surname><given-names>P</given-names></name><name><surname>Shubert</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>F</given-names></name><name><surname>Gebauer</surname><given-names>C</given-names></name><name><surname>Iams</surname><given-names>J</given-names></name></person-group><article-title>A randomised, prospective study of adjunctive ceftizoxime in preterm labor</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>172</volume><fpage>1546</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">7755069</pub-id></mixed-citation></ref><ref id="b40-tcrm-6-191"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyarzun</surname><given-names>E</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Rioscco</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Gutierrez</surname><given-names>P</given-names></name><name><surname>Donoso</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Antibiotic treatment in preterm labor and intact membranes: a randomised, double-blinded, placebo-controlled trial</article-title><source>J Matern Fetal Med</source><year>1998</year><volume>7</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">9642605</pub-id></mixed-citation></ref><ref id="b41-tcrm-6-191"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>SM</given-names></name><name><surname>Boham</surname><given-names>V</given-names></name><name><surname>Sherman</surname><given-names>ML</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name></person-group><article-title>Single-center randomized placebo controlled trial of antimicrobials for prevention of preterm birth</article-title><source>Am J Obstet Gynecol</source><year>1996</year><volume>174</volume><fpage>206</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">8572007</pub-id></mixed-citation></ref><ref id="b42-tcrm-6-191"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>JF</given-names></name><name><surname>Fenady</surname><given-names>V</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name></person-group><article-title>Prophylactic antibiotics for inhibiting preterm labour with intact membranes</article-title><source>Cochrane Database Syst Rev</source><year>2002</year><issue>4</issue><fpage>CD000246</fpage><pub-id pub-id-type="pmid">12519538</pub-id></mixed-citation></ref><ref id="b43-tcrm-6-191"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Dalziel</surname><given-names>SR</given-names></name></person-group><article-title>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><issue>3</issue><fpage>CD004454</fpage><pub-id pub-id-type="pmid">16856047</pub-id></mixed-citation></ref><ref id="b44-tcrm-6-191"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daiziel</surname><given-names>SR</given-names></name><name><surname>Walker</surname><given-names>NK</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1856</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">15924982</pub-id></mixed-citation></ref><ref id="b45-tcrm-6-191"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Repeat doses of prenatal corticocteroids for women at riak of preterm birth for preventing neonatal respiratory disease</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><issue>3</issue><fpage>CD003935</fpage><pub-id pub-id-type="pmid">17636741</pub-id></mixed-citation></ref><ref id="b46-tcrm-6-191"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mckenna</surname><given-names>DS</given-names></name><name><surname>Witber</surname><given-names>GM</given-names></name><name><surname>Nagaraja</surname><given-names>HN</given-names></name><name><surname>Samuels</surname><given-names>P</given-names></name></person-group><article-title></article-title><source>Am J Obstet Gynecol</source><year>2000</year><volume>183</volume><fpage>669</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">10992191</pub-id></mixed-citation></ref><ref id="b47-tcrm-6-191"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>PJ</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Willson</surname><given-names>KJ</given-names></name><etal></etal></person-group><article-title>Neonatal adrenal function after repeat dose prenatal corticosteroids: a randomised controlled trial</article-title><source>Am J Obstet Gynecol</source><year>2006</year><volume>194</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">16522426</pub-id></mixed-citation></ref><ref id="b48-tcrm-6-191"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbassi</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Effect of single versus multiple courses of Antenatal corticosteroids on maternal and neonatal outcome</article-title><source>Am J Obstet Gynecol</source><year>2000</year><volume>182</volume><fpage>1243</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">10819866</pub-id></mixed-citation></ref><ref id="b49-tcrm-6-191"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>NP</given-names></name><name><surname>Hagan</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>SF</given-names></name><name><surname>Mullan</surname><given-names>A</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name></person-group><article-title>Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behaviour</article-title><source>Am J Obstet Gynecol</source><year>2004</year><volume>190</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">15041985</pub-id></mixed-citation></ref><ref id="b50-tcrm-6-191"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrlander</surname><given-names>S</given-names></name><name><surname>Gennser</surname><given-names>G</given-names></name><name><surname>Eneroth</surname><given-names>P</given-names></name></person-group><article-title>Plasma cortisol levels in human fetus during parturition</article-title><source>Obstet Gynecol</source><year>1976</year><volume>48</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">967373</pub-id></mixed-citation></ref><ref id="b51-tcrm-6-191"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>JA</given-names></name><name><surname>Jackson</surname><given-names>GM</given-names></name><name><surname>Lachelin</surname><given-names>GC</given-names></name><etal></etal></person-group><article-title>Salivary estriol as risk assessment for preterm labor: a prospective trial</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>4</volume><fpage>1337</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">7485350</pub-id></mixed-citation></ref><ref id="b52-tcrm-6-191"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>M</given-names></name><name><surname>Bisits</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Woods</surname><given-names>R</given-names></name><name><surname>Lowry</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name></person-group><article-title>A placental clock controlling the length of human pregnancy</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>460</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">7585095</pub-id></mixed-citation></ref><ref id="b53-tcrm-6-191"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandman</surname><given-names>CA</given-names></name><name><surname>Glynn</surname><given-names>L</given-names></name><name><surname>Dunkel Schetter</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Elevated maternal cortisol early in pregnancy predicts third trimester levels of placental corticotrophin releasing hormone (CRH): Priming the placental clock</article-title><source>Peptides</source><year>2006</year><volume>27</volume><fpage>1457</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">16309788</pub-id></mixed-citation></ref><ref id="b54-tcrm-6-191"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>JI</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><etal></etal></person-group><article-title>Patterns of plasma corticotrophin-releasing hormone, progesterone, oestradiol, and oestriol change and the onset of human labor</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>2066</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">19258402</pub-id></mixed-citation></ref><ref id="b55-tcrm-6-191"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liggins</surname><given-names>GC</given-names></name></person-group><article-title>Parturition in the sheep and the human</article-title><source>Basic Life Sci</source><year>1974</year><volume>4</volume><fpage>423</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">4376691</pub-id></mixed-citation></ref><ref id="b56-tcrm-6-191"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AB</given-names></name><name><surname>Flint</surname><given-names>AP</given-names></name><name><surname>Turnbull</surname><given-names>AC</given-names></name></person-group><article-title>Mechanism of action of glucocorticoids in induction of ovine parturition: effect on placental steroid metabolism</article-title><source>J Endocrinol</source><year>1975</year><volume>66</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">1172518</pub-id></mixed-citation></ref><ref id="b57-tcrm-6-191"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>WL</given-names></name><name><surname>Patel</surname><given-names>FA</given-names></name><name><surname>Alfaidy</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Glucocorticoid regulation of human and ovine parturition: the relationship between fetal hypothalamic-pituatary-adrenal axis activation and intrauterine prostaglandin production</article-title><source>Biol Reprod</source><year>2001</year><volume>64</volume><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">11259246</pub-id></mixed-citation></ref><ref id="b58-tcrm-6-191"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez Bernal</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of labour – biochemical aspects</article-title><source>BJOG</source><year>2003</year><volume>110</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12763110</pub-id></mixed-citation></ref><ref id="b59-tcrm-6-191"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novy</surname><given-names>MJ</given-names></name></person-group><article-title>Endocrine and pharmacological factors which influence the onset of Labour in rhesus monkeys</article-title><source>Ciba Found Symp</source><year>1997</year><volume>47</volume><fpage>259</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">205394</pub-id></mixed-citation></ref><ref id="b60-tcrm-6-191"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecanas</surname><given-names>C</given-names></name><name><surname>Giussani</surname><given-names>D</given-names></name><name><surname>Owiny</surname><given-names>JR</given-names></name><etal></etal></person-group><article-title>Production of premature delivery in rhesus monkeys by androstenedione infusion</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">8597955</pub-id></mixed-citation></ref><ref id="b61-tcrm-6-191"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halushka</surname><given-names>GJ</given-names></name><name><surname>Cook</surname><given-names>MJ</given-names></name><name><surname>Novy</surname><given-names>MJ</given-names></name></person-group><article-title>Pulsatile infusion of ACTH into the fetal circulation in rhesus monkeys leads to premature labour and delivery</article-title><source>J Soc Gynecol Invest</source><year>1999</year><volume>6</volume><fpage>61</fpage><comment>(abstract 66)</comment></mixed-citation></ref><ref id="b62-tcrm-6-191"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>WL</given-names></name><name><surname>Gibb</surname><given-names>W</given-names></name><name><surname>Shallis</surname><given-names>JRG</given-names></name></person-group><article-title>The characterization of human amnion epithelial and mesenchymal cells: cellular expression, activity and glucocorticoid regulation of prostaglandin output</article-title><source>Placenta</source><year>2000</year><volume>21</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">10833375</pub-id></mixed-citation></ref><ref id="b63-tcrm-6-191"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>W</given-names></name><name><surname>Breton</surname><given-names>R</given-names></name></person-group><article-title>Studies on the action of dexamethasone on prostaglandin output by freshly dispersed amnion cells</article-title><source>Acta Endocrinol (Copenh)</source><year>1993</year><volume>8</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">8337920</pub-id></mixed-citation></ref><ref id="b64-tcrm-6-191"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Tai</surname><given-names>HH</given-names></name></person-group><article-title>Interleukin-1b and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NFKB pathway in human amnion WISH cells</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>1998</year><volume>59</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">9758209</pub-id></mixed-citation></ref><ref id="b65-tcrm-6-191"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesiano</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>EC</given-names></name><name><surname>Fitter</surname><given-names>JT</given-names></name><etal></etal></person-group><article-title>Progesterone withdrawal and oestrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>2924</fpage><lpage>2930</lpage><pub-id pub-id-type="pmid">12050275</pub-id></mixed-citation></ref><ref id="b66-tcrm-6-191"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelson</surname><given-names>CR</given-names></name><name><surname>Condon</surname><given-names>JC</given-names></name></person-group><article-title>New insights into the molecular endocrinology of parturition</article-title><source>J Steroid Biochem Mol Biol</source><year>2005</year><volume>93</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">15860253</pub-id></mixed-citation></ref><ref id="b67-tcrm-6-191"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allport</surname><given-names>VC</given-names></name><name><surname>Pieber</surname><given-names>D</given-names></name><name><surname>Slater</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title>Human labour is associated with nuclear factor-kB activity which mediates cyclo-oxygenase-2 expression and is involved with ‘functional progesterone withdrawal’</article-title><source>Mol Human Reprod</source><year>2001</year><volume>7</volume><fpage>581</fpage><lpage>586</lpage></mixed-citation></ref><ref id="b68-tcrm-6-191"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindstrom</surname><given-names>TM</given-names></name><name><surname>Bennett</surname><given-names>PR</given-names></name></person-group><article-title>The role of nuclear factor kappa B in human labour</article-title><source>Reproduction</source><year>2005</year><volume>130</volume><fpage>569</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">16264088</pub-id></mixed-citation></ref><ref id="b69-tcrm-6-191"><label>69</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>MD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hillier</surname><given-names>K</given-names></name></person-group><article-title>Regulation of eicosanoid biosynthesis during pregnancy and parturition</article-title><source>Eicosanoids and Reproduction</source><publisher-loc>Lancaster</publisher-loc><publisher-name>MTP Press</publisher-name><year>1987</year></mixed-citation></ref><ref id="b70-tcrm-6-191"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>P</given-names></name><name><surname>Taggart</surname><given-names>MJ</given-names></name><name><surname>Mitchell</surname><given-names>BF</given-names></name></person-group><article-title>Oxytocin and parturition: a role for increased myometrial calcium and calcium sensitisation</article-title><source>Front Biosci</source><year>2007</year><volume>12</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">17127323</pub-id></mixed-citation></ref><ref id="b71-tcrm-6-191"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>CJ</given-names></name><name><surname>Friel</surname><given-names>AM</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Cairns</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>JJ</given-names></name></person-group><article-title>Expression and modulation of Rho kinase in human pregnant myometrium</article-title><source>Mol Hum Reprod</source><year>2002</year><volume>8</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">11818523</pub-id></mixed-citation></ref><ref id="b72-tcrm-6-191"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Europe-Finner</surname><given-names>GN</given-names></name><name><surname>Phaneuf</surname><given-names>S</given-names></name><name><surname>Tolkovsky</surname><given-names>AM</given-names></name><name><surname>Watson</surname><given-names>SP</given-names></name><name><surname>Lopez Bernal</surname><given-names>A</given-names></name></person-group><article-title>Down-regulation of G alpha s in human myometrium in term and preterm labor: a mechanism for parturition</article-title><source>J Clin Endocrinol Metab</source><year>1994</year><volume>79</volume><fpage>1835</fpage><lpage>1839</lpage><pub-id pub-id-type="pmid">7989491</pub-id></mixed-citation></ref><ref id="b73-tcrm-6-191"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehats</surname><given-names>C</given-names></name><name><surname>Tanguy</surname><given-names>B</given-names></name><name><surname>Paris</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors</article-title><source>J Pharmacol Exp Ther</source><year>2000</year><volume>292</volume><fpage>817</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">10640323</pub-id></mixed-citation></ref><ref id="b74-tcrm-6-191"><label>74</label><mixed-citation publication-type="journal"><article-title>Oxytocin receptors in pregnant human uterus and regulation of oxytocin action during pregnancy and parturition</article-title><source>Am J Obstet Gynecol</source><year>1984</year><volume>150</volume><fpage>138</fpage><lpage>143</lpage></mixed-citation></ref><ref id="b75-tcrm-6-191"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>KYR</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>Developments in the pharmacotherapeutic management of spontaneous preterm labor</article-title><source>Expert Opin Pharmacother</source><year>2008</year><volume>9</volume><fpage>1153</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">18422473</pub-id></mixed-citation></ref><ref id="b76-tcrm-6-191"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>The development and introduction of anti-oxytocic tocolytics</article-title><source>BJOG</source><year>2003</year><volume>110</volume><issue>Suppl 20</issue><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">12763125</pub-id></mixed-citation></ref><ref id="b77-tcrm-6-191"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyndrup</surname><given-names>J</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>The choice of tocolytic for the treatment of preterm labour: a critical evaluation of nifedipine versus atosiban</article-title><source>Expert Opin Investig Drugs</source><year>2007</year><volume>16</volume><fpage>843</fpage><lpage>853</lpage></mixed-citation></ref><ref id="b78-tcrm-6-191"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name><name><surname>Kam</surname><given-names>KYR</given-names></name></person-group><article-title>Atosiban for the treatment of spontaneous preterm labor</article-title><source>Expert Rev Obstet Gynecol</source><year>2008</year><volume>3</volume><fpage>163</fpage><lpage>174</lpage></mixed-citation></ref><ref id="b79-tcrm-6-191"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkin</surname><given-names>G</given-names></name></person-group><article-title>Oxytocin and prostaglandin interactions in pregnancy and at parturition</article-title><source>J Reprod Fertil Suppl</source><year>1992</year><volume>45</volume><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">1304035</pub-id></mixed-citation></ref><ref id="b80-tcrm-6-191"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husslein</surname><given-names>P</given-names></name><name><surname>Fuchs</surname><given-names>AR</given-names></name><name><surname>Fuchs</surname><given-names>F</given-names></name></person-group><article-title>Oxytocin and the initiation of human parturition. 11. Stimulation of prostaglandin production in human deciduas by oxytocin</article-title><source>Am J Obstet Gynecol</source><year>1981</year><volume>141</volume><fpage>694</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">7315896</pub-id></mixed-citation></ref><ref id="b81-tcrm-6-191"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundin</surname><given-names>S</given-names></name><name><surname>Akerlund</surname><given-names>M</given-names></name><name><surname>Fagerstrom</surname><given-names>PO</given-names></name><name><surname>Hauksson</surname><given-names>A</given-names></name><name><surname>Melin</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist</article-title><source>Acta Endocrinol (Copenh)</source><year>1986</year><volume>112</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">3751461</pub-id></mixed-citation></ref><ref id="b82-tcrm-6-191"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>TM</given-names></name><name><surname>Millar</surname><given-names>L</given-names></name><name><surname>North</surname><given-names>L</given-names></name><name><surname>Abrams</surname><given-names>LS</given-names></name><name><surname>Weglein</surname><given-names>RC</given-names></name><name><surname>Holland</surname><given-names>ML</given-names></name></person-group><article-title>The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>173</volume><fpage>913</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">7573268</pub-id></mixed-citation></ref><ref id="b83-tcrm-6-191"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>TM</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Silver</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>170</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">8116700</pub-id></mixed-citation></ref><ref id="b84-tcrm-6-191"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Sibai</surname><given-names>BM</given-names></name><name><surname>Sanchez-Ramos</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue</article-title><source>Am J Obstet Gynecol</source><year>2000</year><volume>182</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">10819855</pub-id></mixed-citation></ref><ref id="b85-tcrm-6-191"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papatsonis</surname><given-names>D</given-names></name><name><surname>Flenady</surname><given-names>V</given-names></name><name><surname>Cole</surname><given-names>S</given-names></name><name><surname>Liley</surname><given-names>H</given-names></name></person-group><article-title>Oxytocin receptor antagonists for inhibiting preterm labor</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><issue>3</issue></mixed-citation></ref><ref id="b86-tcrm-6-191"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname><given-names>GJ</given-names></name><name><surname>Sanchez-Ramos</surname><given-names>L</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group</article-title><source>Am J Obstet Gynecol</source><year>2000</year><volume>18</volume><fpage>1184</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">10819856</pub-id></mixed-citation></ref><ref id="b87-tcrm-6-191"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutquin</surname><given-names>JM</given-names></name><name><surname>Cabrol</surname><given-names>D</given-names></name><name><surname>Fisk</surname><given-names>NM</given-names></name></person-group><article-title>Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group</article-title><source>BJOG</source><year>2001</year><volume>108</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">11236112</pub-id></mixed-citation></ref><ref id="b88-tcrm-6-191"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coomarasamy</surname><given-names>A</given-names></name><name><surname>Knox</surname><given-names>EM</given-names></name><name><surname>Gee</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>KS</given-names></name></person-group><article-title>Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials</article-title><source>BJOG</source><year>2003</year><volume>110</volume><fpage>1045</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">14664874</pub-id></mixed-citation></ref><ref id="b89-tcrm-6-191"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Omari</surname><given-names>WR</given-names></name><name><surname>Al-Shammaa</surname><given-names>HB</given-names></name><name><surname>Al-Tikriti</surname><given-names>EM</given-names></name><name><surname>Ahmed</surname><given-names>KW</given-names></name></person-group><article-title>Atosiban and nifedipine in acute tocolysis: a comparative study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2006</year><volume>128</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16446025</pub-id></mixed-citation></ref><ref id="b90-tcrm-6-191"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashanian</surname><given-names>M</given-names></name><name><surname>Akbarian</surname><given-names>AR</given-names></name><name><surname>Soltanzadeh</surname><given-names>M</given-names></name></person-group><article-title>Atosiban and nifedipin for the treatment of preterm labor</article-title><source>Int J Gynecol Obstet</source><year>2005</year><volume>91</volume><fpage>10</fpage><lpage>14</lpage></mixed-citation></ref><ref id="b91-tcrm-6-191"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ervin</surname><given-names>MG</given-names></name></person-group><article-title>Perinatal fluid and electrolyte regulation: role of arginine vasopressin</article-title><source>Semin Perinatol</source><year>1998</year><volume>12</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">3293224</pub-id></mixed-citation></ref><ref id="b92-tcrm-6-191"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>PC</given-names></name><name><surname>Massmann</surname><given-names>GA</given-names></name><name><surname>Demarest</surname><given-names>KT</given-names></name><etal></etal></person-group><article-title>Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep</article-title><source>Am J Obstet Gynecol</source><year>1993</year><volume>169</volume><fpage>897</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">8238146</pub-id></mixed-citation></ref><ref id="b93-tcrm-6-191"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname><given-names>GJ</given-names></name><name><surname>Craig</surname><given-names>J</given-names></name><name><surname>Bernhardt</surname><given-names>MD</given-names></name><name><surname>Holland</surname><given-names>ML</given-names></name></person-group><article-title>Placental passage of the oxytocin antagonist atosiban</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>172</volume><fpage>1304</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">7726274</pub-id></mixed-citation></ref><ref id="b94-tcrm-6-191"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blea</surname><given-names>CW</given-names></name><name><surname>Barnard</surname><given-names>JM</given-names></name><name><surname>Magness</surname><given-names>RR</given-names></name><name><surname>Phernetton</surname><given-names>TM</given-names></name><name><surname>Hendricks</surname><given-names>SK</given-names></name></person-group><article-title>Effect of nifedipine on fetal and maternal hemodynamics and blood gases</article-title><source>Am J Obstet Gynecol</source><year>1997</year><volume>176</volume><fpage>922</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">9125622</pub-id></mixed-citation></ref><ref id="b95-tcrm-6-191"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oei</surname><given-names>SG</given-names></name><name><surname>Oei</surname><given-names>SK</given-names></name><name><surname>Brolmann</surname><given-names>HA</given-names></name></person-group><article-title>Myocardial infarction during nifedipine therapy for preterm labor</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>154</fpage><pub-id pub-id-type="pmid">9917222</pub-id></mixed-citation></ref><ref id="b96-tcrm-6-191"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaast</surname><given-names>P</given-names></name><name><surname>Dubreuq-Fossaert</surname><given-names>S</given-names></name><name><surname>Houfflin-Debarge</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Acute pulmonary oedema during nicardipine therapy for premature labour; report of five cases</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2004</year><volume>113</volume><fpage>98</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">15036720</pub-id></mixed-citation></ref><ref id="b97-tcrm-6-191"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahaert</surname><given-names>D</given-names></name><name><surname>Van</surname><given-names>AR</given-names></name></person-group><article-title>Acute myocardial infarction during pregnancy</article-title><source>Acta Cardiol</source><year>2004</year><volume>111</volume><fpage>380</fpage><lpage>381</lpage></mixed-citation></ref><ref id="b98-tcrm-6-191"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname><given-names>R</given-names></name><name><surname>Barkehall-Thomas</surname><given-names>A</given-names></name><name><surname>Tippett</surname><given-names>C</given-names></name></person-group><article-title>Maternal hypoxia associated with nifedipine for threatened preterm labour</article-title><source>BJOG</source><year>2004</year><volume>111</volume><fpage>380</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">15008777</pub-id></mixed-citation></ref><ref id="b99-tcrm-6-191"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bal</surname><given-names>L</given-names></name><name><surname>Thierry</surname><given-names>S</given-names></name><name><surname>Brocas</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Pulmonary edema induced by calciumchannel blockade for tocolysis</article-title><source>Anesth Analg</source><year>2004</year><volume>99</volume><fpage>910</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">15333430</pub-id></mixed-citation></ref><ref id="b100-tcrm-6-191"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Impey</surname><given-names>L</given-names></name></person-group><article-title>Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy-induced hypertension at 33 weeks</article-title><source>BJOG</source><year>1993</year><volume>100</volume><fpage>959</fpage><lpage>961</lpage></mixed-citation></ref><ref id="b101-tcrm-6-191"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Veen</surname><given-names>AJ</given-names></name><name><surname>Pelinck</surname><given-names>MJ</given-names></name><name><surname>Van Pampus</surname><given-names>MG</given-names></name><name><surname>Erwich</surname><given-names>JJ</given-names></name></person-group><article-title>Severe hypotension and fetal death due to tocolysis with nifedipine</article-title><source>BJOG</source><year>2005</year><volume>112</volume><fpage>509</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">15777455</pub-id></mixed-citation></ref><ref id="b102-tcrm-6-191"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parasurraman</surname><given-names>R</given-names></name><name><surname>Gandhi</surname><given-names>MM</given-names></name><name><surname>Liversedge</surname><given-names>NH</given-names></name></person-group><article-title>Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion</article-title><source>BJOG</source><year>2006</year><volume>113</volume><fpage>844</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">16827771</pub-id></mixed-citation></ref><ref id="b103-tcrm-6-191"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Mason</surname><given-names>GC</given-names></name></person-group><article-title>Severe hypotension and fetal death due to tocolysis with nifedipine</article-title><source>BJOG</source><year>2005</year><volume>112</volume><fpage>1583</fpage><pub-id pub-id-type="pmid">16225589</pub-id></mixed-citation></ref><ref id="b104-tcrm-6-191"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandysamy</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group><article-title>Severe hypotension and fetal death due to tocolysis with nifedipine</article-title><source>BJOG</source><year>2005</year><volume>112</volume><fpage>1582</fpage><lpage>1584</lpage></mixed-citation></ref><ref id="b105-tcrm-6-191"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donders</surname><given-names>GG</given-names></name><name><surname>Van Keirsbilick</surname><given-names>J</given-names></name><name><surname>De Roo</surname><given-names>T</given-names></name><name><surname>Schreven</surname><given-names>L</given-names></name><name><surname>Hanssens</surname><given-names>M</given-names></name></person-group><article-title>Non-cardiogenic lung edema in a woman treated with atosiban for preterm labor</article-title><source>J Perinat Med</source><year>2008</year><volume>36</volume><fpage>455</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">18605966</pub-id></mixed-citation></ref><ref id="b106-tcrm-6-191"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name></person-group><article-title>Commentary: A case of non-cardiogenic lung edema in a woman treated with atosiban for preterm labor</article-title><source>J Perinat Med</source><year>2008</year><volume>36</volume><fpage>458</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">18771411</pub-id></mixed-citation></ref><ref id="b107-tcrm-6-191"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Zamora</surname><given-names>J</given-names></name><name><surname>Lamont</surname><given-names>RF</given-names></name><etal></etal></person-group><article-title>Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis</article-title><source>J Matern Fetal Neonatal Med</source><year>2010</year><month>2</month><day>25</day><comment>[Epub ahead of print]</comment></mixed-citation></ref><ref id="b108-tcrm-6-191"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houtzager</surname><given-names>BA</given-names></name><name><surname>Hogendoorn</surname><given-names>SM</given-names></name><name><surname>Papatsonis</surname><given-names>DNN</given-names></name><etal></etal></person-group><article-title>Long-term follow up of children exposed in-utero to nifedipine or ritodrine for the management of preterm labour</article-title><source>BJOG</source><year>2006</year><volume>113</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">16487205</pub-id></mixed-citation></ref><ref id="b109-tcrm-6-191"><label>109</label><mixed-citation publication-type="webpage"><collab>British National Formulary</collab><comment>website: <ext-link ext-link-type="uri" xlink:href="http://bnf.org">http://bnf.org</ext-link></comment><date-in-citation>Accessed September 2009</date-in-citation></mixed-citation></ref><ref id="b110-tcrm-6-191"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name><name><surname>Khan</surname><given-names>KS</given-names></name><name><surname>Beattie</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review</article-title><source>J Perinat Med</source><year>2005</year><volume>33</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">16207113</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="f1-tcrm-6-191" position="float"><label>Figure 1</label><caption><p>Flow chart of biochemical events leading to preterm labor.</p></caption><graphic xlink:href="tcrm-6-191f1"></graphic></fig></floats-group></article>